Abstract
There is evidence of a different response to treatment with regard to the primary tumor localization (right-sided or left-sided) in patients with metastatic colorectal cancer (mCRC). We analyzed the different outcomes and biomolecular characteristics in relation to tumor localization in 122 of the 370 patients with metastatic colorectal cancer enrolled onto the phase III prospective multicenter “Italian Trial in Advanced Colorectal Cancer (ITACa)”, randomized to receive first-line chemotherapy (CT) or CT plus bevacizumab (CT + B). RAS and BRAF mutations; baseline expression levels of circulating vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), cyclooxygenase-2 (COX2), ephrin type-B receptor 4 (EPHB4), hypoxia-inducible factor 1-alpha (HIF-1α), lactate dehydrogenase (LDH), and high-sensitivity C reactive protein (hs-CRP); and inflammatory indexes such as the neutrophil-to-lymphocyte ratio, platelet-lymphocyte rate and systemic immune-inflammation index were evaluated. Patients with right-sided tumors showed a longer median progression-free survival in the CT + B arm than in the CT group (12.6 vs. 9.0 months, respectively, p = 0.017). Baseline inflammatory indexes were significantly higher in left-sided tumors, whereas eNOS and EPHB4 expression was significantly higher and BRAF mutation more frequent in right-sided tumors. Our data suggest a greater efficacy of the CT + B combination in right-sided mCRC, which might be attributable to the lower inflammatory status and higher expression of pro-angiogenic factors that appear to characterize these tumors.
Highlights
Colorectal cancer is a heterogeneous disease that can develop in different parts of the colon, with consequent differences in terms of risk factor, histological grade, tumor size and metastatic features [1,2]
In addition to its prognostic relevance, there is evidence to suggest that tumor localization may be predictive of treatment efficacy with targeted agents, especially those directed against epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways [3,5,6,7,8,9,10]
We decided to investigate B efficacy, the distribution of a series of parameters involved in angiogenesis and inflammatory processes, and RAS and BRAF mutations in relation to tumor localization in a case series of metastatic colorectal cancer patients enrolled in the phase III multicenter, prospective, randomized “Italian Trial in Advanced Colorectal Cancer (ITACa)” trial
Summary
Colorectal cancer is a heterogeneous disease that can develop in different parts of the colon, with consequent differences in terms of risk factor, histological grade, tumor size and metastatic features [1,2]. In addition to its prognostic relevance, there is evidence to suggest that tumor localization may be predictive of treatment efficacy with targeted agents, especially those directed against EGFR and vascular endothelial growth factor (VEGF) pathways [3,5,6,7,8,9,10] Data on this specific topic are discordant due to the heterogeneity of the studies carried out, left-sided RAS wild type (wt) tumors appear to be more responsive to EGFR inhibitors, possibly due to the higher frequency of BRAF mutations in right-sided disease [2,7,9,11]. We decided to investigate B efficacy, the distribution of a series of parameters involved in angiogenesis and inflammatory processes, and RAS and BRAF mutations in relation to tumor localization in a case series of metastatic colorectal cancer patients enrolled in the phase III multicenter, prospective, randomized “Italian Trial in Advanced Colorectal Cancer (ITACa)” trial [21] The ITACa trial is registered on ClinicalTrials.gov (NCT01878422)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
